January 11, 2021 -- The first patient has been dosed in a phase I clinical trial being conducted by Codagenix and the Serum Institute of India of COVI-Vac, a single-dose, intranasal vaccine against the SARS-CoV-2 virus.
Codagenix and the Serum Institute of India announced the start of the phase I trial in December following regulatory approval from the U.K. Medicines and Healthcare Products Regulatory Agency. It is operating as a randomized, double-blinded, placebo-controlled dose-escalation study among 48 volunteers.
Open Orphan subsidiary hVIVO is conducting the study, which will evaluate COVI-Vac's safety and tolerability as well as its ability to provoke an immune response. The formulation has the advantage of only requiring a single dose and not needing a needle, syringe, or ultra-low-temperature storage.
Codagenix intends to report initial data by the middle of this year, with plans to begin advanced clinical testing soon after.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
